SCHEMBL3269795

SCHEMBL3269795

Nc1nc(Cl)c2ncn(Cc3ccccc3F)c2n1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 1/20 0.64
ADORA1 P30542 1/20 0.64
HDAC6 Q9UBN7 5/20 0.63
HDAC1 Q13547 4/20 0.57
HDAC2 Q92769 2/20 0.57
HDAC4 P56524 2/20 0.57
HDAC3 O15379 1/20 0.57
HDAC7 Q8WUI4 1/20 0.57
HDAC10 Q969S8 1/20 0.57
HDAC11 Q96DB2 1/20 0.57
HDAC8 Q9BY41 1/20 0.57
HDAC9 Q9UKV0 1/20 0.57
HDAC5 Q9UQL6 1/20 0.57
HSP90AB1 P08238 10/20 0.56
HSP90AA1 P07900 9/20 0.56
PDE4A P27815 2/20 0.51
PDE4B Q07343 2/20 0.51
PDE4C Q08493 2/20 0.51
PDE4D Q08499 2/20 0.51
PDE5A O76074 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9738574 0.87 ADORA2A (0.66) ADORA2AADORA1HDAC6HSP90AB1HSP90AA1
SCHEMBL23416524 0.86 ADORA2A (0.63) ADORA2AADORA1HDAC6HDAC1HDAC2
SCHEMBL3138769 0.82 PDE4A (0.70) ADORA2AADORA1HDAC6HDAC1HDAC2
SCHEMBL6272417 0.82 ALDH1A1 (0.66) ADORA2AADORA1HDAC6HDAC1HDAC2
SCHEMBL3268278 0.81 ADORA2A (0.60) ADORA2AADORA1HDAC6PDE4APDE4B
SCHEMBL9739023 0.81 PDE4A (0.72) ADORA2AADORA1HDAC6PDE4APDE4B
SCHEMBL9738116 0.81 ADORA2A (0.60) ADORA2AADORA1HDAC6PDE4APDE4B
SCHEMBL3269162 0.81 ADORA2A (0.60) ADORA2AADORA1HDAC6PDE4APDE4B
SCHEMBL3268280 0.81 ADORA2A (0.57) ADORA2AADORA1HDAC6HDAC1HDAC2
SCHEMBL3390714 0.81 HDAC6 (0.54) ADORA2AADORA1HDAC6HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1349857-B1 PURINE DERIVATIVES AS PURINERGIC RECEPTOR ANTAGONISTS VERNALIS RES LTD (GB) 2010-06-16 EP disclosed
US-7452894-B2 Purine derivatives as purinergic receptor antagonists VERNALIS RESEARCH LIMITED (GB) 2008-11-18 US disclosed
US-20060270691-A1 Purine derivatives as purinergic receptor antagonists VERNALIS RESEARCH LIMITED 2006-11-30 US disclosed
CN-1617871-A Purine derivatives as purinergic receptor antagonists VERNALIS RES LTD (GB) 2005-05-18 CN disclosed
US-20040102459-A1 Purine derivatives as purinergic receptor antagonists VERNALIS RESEARCH LIMITED (GB) 2004-05-27 US disclosed
EP-1349857-A1 PURINE DERIVATIVES AS PURINERGIC RECEPTOR ANTAGONISTS VERNALIS RESEARCH LIMITED (GB) 2003-10-08 EP disclosed
WO-2002055521-A1 PURINE DERIVATIVES AS PURINERGIC RECEPTOR ANTAGONISTS VERNALIS RESEARCH LIMITED (GB) 2002-07-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060270691-A1 Purine derivatives as purinergic receptor antagonists CHRNA10, CHRNA5, CHRNA4 ADORA2A 14/4885ADORA1 17/4885HDAC6 3406/4885
US-20040102459-A1 Purine derivatives as purinergic receptor antagonists OPRL1, CNR1, CNR2 ADORA2A 13/4885ADORA1 28/4885HDAC6 2987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.